- Raised $6.6M Series B, Dec 2024
- Raised $5M Series A, Jul 2019
- Raised $2.6M A Round Extension, Feb 2021
About
Pepticom is a biotechnology company that utilizes an AI-driven platform for peptide drug discovery. The company's technology combines principles from economic and molecular mechanics, reinforcement learning, first-principles modeling, and generative AI to design and discover novel peptides with high success rates, aiming to reduce research and development time and costs. Pepticom's platform can explore a vast chemical space of potential peptide structures, including linear, helical, and cyclic peptides, and incorporate D and non-natural amino acids. The company is involved in discovery projects with academic and industry partners and has several molecules in different development stages. In March 2021, Pepticom established a spin-off company, PeptiCov, to focus on developing treatments for the SARS-CoV-2 virus. Pepticom is currently advancing an AI-designed therapeutic peptide for psoriasis, with plans to announce its first drug candidate during 2025 and expand its drug pipeline indications.
Funding history · 4 rounds · $14.2M total
Headcount over time
Q&A
- What is Pepticom's primary focus?
- Pepticom is a biotechnology company that develops an AI-driven platform for peptide drug discovery, aiming to accelerate and optimize the development of peptide-based therapeutics.
- What was Pepticom's most recent funding round?
- Japan Israel High Tech Ventures 2 LP was a lead investor in this round.
- What was Pepticom's previous funding round before January 2025?
- In March 2021, Pepticom completed an A Round, raising $2.6 million. Chartered Group was a lead investor in this round.
- What is Pepticom's total funding raised to date?
- Pepticom has raised a total of $14.2 million USD across all funding rounds.
- What is Pepticom's current stage of funding?
- Pepticom is currently in the Series A funding stage.
- Does Pepticom have any spin-off companies?
- Yes, in March 2021, Pepticom established a spin-off company named PeptiCov, which focuses on developing treatments for the SARS-CoV-2 virus.
- What is Pepticom's current drug development focus?
- Pepticom is currently advancing an AI-designed therapeutic peptide for psoriasis and plans to announce its first drug candidate during 2025, with intentions to expand its drug pipeline indications.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | pepticom.com |
|---|---|
| linkedin.com/company/13182242 | |
| YouTube | youtube.com/channel/UCw2nwNKaAM7ZGksw7eilEJw |
Identifiers & details
| Founded | 2011 |
|---|---|
| Employees (exact) | 16 |
Radar intelligence
Patents
| EPO | 6 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | pepticom.com |
|---|
Certificate / subdomain footprint
| Subdomains | 4 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514691880 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-12-01 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — shares_capital (1) |
| Registered address | כפר ההיטק גבעת רם 2 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2025-08-20 | הקצאת מניות |